Does Combination Therapy With SGLT2 Inhibitors and Renin–Angiotensin System Blockers Lead to Greater Reduction in Cardiorenal Events Among Patients With Type 2 Diabetes?

Frontiers in Cardiovascular Medicine

article

Li-Min Zhao¹  Miao Zhang²  Ze-Lin Zhan³  Mei Qiu⁴ 

[1] Department of Endocrinology, Shenzhen Longhua District Central Hospital;Department of Nephrology, Shenzhen Hospital of Beijing University of Chinese Medicine;Clinical Medicine, The Second Clinical Medical College, Southern Medical University;Department of General Medicine, Shenzhen Longhua District Central Hospital

关键词: SGLT2 inhibitors;    RAS blockers;    type 2 diabetes mellitus;    cardiorenal events;    Heart failure;   

DOI  :  10.3389/fcvm.2021.679124

学科分类：地球科学(综合)

来源: Frontiers

【 摘 要 】

We have read with great interest a meta-analysis (1) entitled “Efficacy and safety of Combination Therapy with Sodium-glucose Transporter 2 Inhibitors and Renin-Angiotensin System Blockers in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis” conducted by Tian et al. In that meta-analysis (1), Tian and colleagues identified that, compared with the monotherapy of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), the combination therapy with sodium-glucose cotransporter 2 (SGLT2) inhibitors and ACEI/ARB led to greater improvement in some of the intermediate indicators such as blood pressure, blood glucose, and estimated glomerular filtration rate (eGFR) among patients with type 2 diabetes mellitus (T2DM). However, the authors failed to assess any of the final outcomes such as cardiovascular events and renal events. Because whether the combination therapy above has superiority over monotherapy in lowering cardiorenal events means a lot to the selection between them, we carried out this meta-analysis based on the cardiovascular or renal outcome trials (CVOTs) assessing gliflozins in T2DM patients.

【 授权许可】

CC BY